Temasek-backed Glympse Bio, a biotechnology company that transforms disease detection and predict treatment response, completed the merger with Sunbird Bio, a biotechnology company developing proprietary protein-based technologies to improve diagnosis and treatment of neurological disorders and early-stage cancer, in a $23.2m deal. “I am excited about the synergies and opportunities created by the integration of our two innovative companies – particularly the impact our combined diagnostic offerings could have on accelerating clinical research and the availability of new treatments for patients suffering from serious diseases. The APEX and Glympse platforms have the potential to dramatically improve standards of care for many diseases by overcoming the inaccessibility, invasiveness, and lack of reliability associated with current diagnostic approaches that limit their usefulness in drug development, disease detection, disease monitoring, and personalized treatment selection,” John McDonough, Sunbird Bio Executive Chair and CEO.